Orient Europharma Co

What Orient Europharma Co does

Orient EuroPharma Co., Ltd. (友華生技) is a Taipei-headquartered, Taiwan-listed pharmaceutical and healthcare company founded in 1978 that operates across 10 markets in Asia-Pacific and North America via wholly-owned subsidiaries. It organizes its business around five product categories—prescription medicines (notably cardiovascular), innovative medical treatments (including TissueTech), baby healthcare (led by the 35-year-old Karolacton/卡洛塔妮 brand), adult healthcare supplements, and dermo-cosmetics (including the ISISPHARMA line)—and is increasingly positioning itself as a regional commercialization gateway for foreign innovators seeking Taiwan and APAC market access.

The company's revenue model combines direct pharmaceutical sales to hospitals and pharmacies in Taiwan with regional subsidiary-led distribution, e-commerce channels (Shopee, Lazada) for consumer health products, and an exclusive commercialization/licensing model for partnered assets. Named in-licensed and partnered products include Trogarzo (ibalizumab, TaiMed Biologics), Multikine (CEL-SCI), Olutasidenib (Reata/Novo Nordisk), and a dermatology collaboration with Japan's Maruho. Corporate structure includes manufacturing subsidiaries 友霖生技 (Uphold BioPharma) and 友杏生技, plus an R&D vehicle OEP Innovations; an additional biotech-AI collaboration with Vernus AI (a Compal Electronics affiliate) targets drug discovery applications using quantum- and GPU-accelerated molecular docking.

Recent strategic activity is partnership-led: 2024–2026 has brought the Trogarzo exclusive deal (May 2024, TFDA license notice July 2026), the CEL-SCI Multikine Phase 3 partnership, the Maruho dermatology partnership (Jan 2026), the Olutasidenib Taiwan rights acquisition (May 2026), and Karolacton's 35th anniversary Rakuten Stadium activation (Apr 2026). Reported financials show revenue contraction from a 2021 peak through 2024 with a partial 2025 rebound, and net losses in 3 of 5 years, indicating that growth momentum is being pursued through new product licensing rather than underlying organic volume.

Name

Orient Europharma Co

Legal name

Orient EuroPharma Co., Ltd.

Website

https://oep.com.tw

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

101–250 employees

Short description

Orient EuroPharma Co., Ltd. (友華生技) is a Taiwan-based pharmaceutical and healthcare company that commercializes prescription medicines, innovative therapies, baby/adult nutrition, and dermo-cosmetics across 10 Asia-Pacific and US markets, acting as a regional gateway for foreign pharma innovators seeking market access.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Consumer Healthcare

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Prescription pharmaceuticals
• Infant nutrition supplements
• Dermo-cosmetic products
• Biotech licensing partnerships
• Innovative medical therapies

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Pharmaceutical commercialization: Revenue generated through commercialization rights for partnered pharmaceutical products in Taiwan and Asian markets, including regulatory registration, marketing, and sales operations.
2. Food supplements and healthcare products: Sales of nutritional supplements, probiotics, and health products through retail channels across Taiwan and Southeast Asian markets.
3. AI/biotech platform services: Collaboration with technology partners for biotech AI platform development in drug discovery applications.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Orient EuroPharma develops, licenses, and commercializes a diversified pharmaceutical and consumer healthcare portfolio spanning five categories: prescription medicines (notably cardiovascular), innovative medical therapies (including TissueTech), baby healthcare nutrition (including the Karolacton brand), adult healthcare supplements, and dermo-cosmetics (including ISISPHARMA). The company also serves as a regional commercialization partner for international biotech firms, securing Taiwan and Asian marketing rights for products such as Trogarzo (ibalizumab) for HIV and Olutasidenib for acute myeloid leukemia.

Product overview

Orient EuroPharma Co is an Asia-Pacific focused pharmaceutical and biotechnology company offering a diversified portfolio of healthcare products across five main categories: Prescription Medicine (處方用藥), Innovative Medical (創新醫療), Baby Healthcare (嬰幼兒保健), Adult Healthcare (成人保健), and Dermo Cosmetics (醫學美容). The company operates through subsidiaries including 友霖生技 and 友杏生技, and maintains strategic partnerships for product licensing and commercialization including Trogarzo for HIV treatment. The product portfolio spans from prescription cardiovascular medications and innovative medical therapies to nutritional supplements for infants, adults, and medical aesthetics solutions.

Differentiator

Problem solved

Functional benefit

Brands

• 卡洛塔妮 (Karolacton): Family nutrition and healthcare brand, celebrating 35th anniversary in 2026
• 信達雅
• TissueTech
• ISISPHARMA

Products and services

• Prescription Medicine (處方用藥) Prescription medications including cardiovascular treatments, distributed to healthcare providers and pharmacies across Taiwan and international markets.
• Innovative Medical (創新醫療) Advanced medical treatments and therapies including TissueTech products, representing cutting-edge healthcare solutions for serious and specialized conditions.
• Baby Healthcare (嬰幼兒保健) - Karolacton (卡洛塔妮) Nutritional and healthcare products for infants and young children, including the Karolacton (卡洛塔妮) brand, a 35-year family nutrition franchise.
• Adult Healthcare (成人保健) Health supplements and wellness products for adult consumers, supporting nutrition, immunity, and preventive care across Asia-Pacific markets.
• Dermo-Cosmetics (醫學美容) - ISISPHARMA Medical aesthetics and dermatological products including the ISISPHARMA brand for skin care treatments and dermo-cosmetic solutions.
• Trogarzo (ibalizumab) HIV Therapy The world's first and only CD4-directed monoclonal antibody approved for treating multidrug-resistant HIV-1 infection in heavily treatment-experienced adults; commercialized in Taiwan by Orient EuroPharma under an exclusive partnership with TaiMed Biologics.
• Olutasidenib (Acute Myeloid Leukemia Therapy) An innovative therapy for acute myeloid leukemia (AML), in-licensed by Orient EuroPharma for development and commercialization in Taiwan.

Quantifiable outcome

• Phase 3 clinical trial showing 73% five-year survival rate with Multikine treatment vs 45% with standard of care
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• CEL-SCI CorporationcoreStrategic or Co-development Partner · 13 July 2026Orient EuroPharma serves as CEL-SCI's strategic partner in Taiwan for the Multikine Phase 3 clinical trial. Orient EuroPharma oversees and funds patient enrollment within its territory for the 212-patient global study targeting newly diagnosed head and neck cancer patients with low or zero PD-L1 expression.
• Reata Pharmaceuticals / Novo NordiskcoreChannel Partner/ Reseller/ Distributor · 5 May 2026Oriental Union Holding (友華生技醫藥) obtained development and commercialization rights in Taiwan for Olutasidenib, an innovative therapy for acute myeloid leukemia (AML), expanding the company's oncology portfolio.
• MaruhocoreStrategic or Co-development Partner · 22 January 2026Orient EuroPharma partnered with Japanese dermatology pharmaceutical company Maruho for product collaboration announced in January 2026, strengthening the company's presence in the dermatology and medical aesthetics segment.
• TaiMed BiologicscoreChannel Partner/ Reseller/ Distributor · 1 May 2024Orient EuroPharma entered into an exclusive commercialization agreement with TaiMed Biologics for the HIV therapy Trogarzo (ibalizumab) in the Taiwan market. TaiMed handles product supply while Orient EuroPharma manages regulatory registration, marketing, and commercialization. Trogarzo received TFDA Drug License Collection Notice in July 2026, marking the final step toward commercial launch.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Center Laboratories: Taiwan specialty pharma with oncology, immunology, and consumer health lines. Comparable given similar specialty pharma positioning and APAC market focus.
• TTY Biopharm: Taiwan-based specialty pharma with similar diversified prescription, oncology, and consumer health portfolio. Most direct comparable given overlapping therapeutic categories (oncology, specialty) and APAC commercialization model.
• ScinoPharm Taiwan: Taiwan-listed specialty/API manufacturer serving global pharma partners. Comparable as a Taiwan-based pharma with partner-driven commercialization model and oncology/specialty focus.
• Standard Chemical & Pharmaceutical: Taiwan-listed pharma manufacturer with prescription and OTC generics plus contract manufacturing. Comparable as a domestic Taiwanese pharma operating across cardiovascular, dermatology, and consumer health segments.
• Yung Shin Pharmaceutical Industrial: Taiwan pharma with diversified prescription, animal health, and consumer health businesses. Comparable scale and product breadth including OTC supplements and prescription pharma with APAC distribution.

Broad incumbents

• Maruho: Japanese dermatology specialty leader and OEP's January 2026 strategic partner. Comparable given shared dermatology focus, though Maruho operates as a Japan-headquartered incumbent with deeper Japan dermatology franchise.
• Daiichi Sankyo: Japan-headquartered global pharma with strong cardiovascular and specialty pipeline and APAC presence. Comparable as a regional incumbent operating across the same therapeutic categories (cardio, oncology, dermatology) that OEP commercializes in Asia.

Emerging players

• PharmaEngine: Taiwan oncology-focused biotech with in-licensed and proprietary pipeline. Overlaps with OEP's oncology commercialization role (e.g., Olutasidenib territory) and APAC distribution model.
• TaiMed Biologics: Taiwan-based biopharma developing and supplying Trogarzo (ibalizumab) for HIV. Direct commercial partner rather than direct competitor, but operates in adjacent oncology/infectious disease specialty biopharma space.

Regional players

• Lupin (Taiwan operations): India-headquartered generic and specialty pharma with APAC distribution partnerships. Comparable as a multinational pharma leveraging partner-led Asia commercialization, including Taiwan and Southeast Asia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orient Europharma Co